Disease modifying agents capable of controlling obesity with meaningful metabolic improvement have reshaped expectations for both clinicians and patients ( Nausea and vomiting remain among the most frequent and disruptive adverse effects across Glucagon-like peptide (GLP-1)-based therapies ( In this opinion article, we examine the mechanisms underlying nausea and vomiting in semaglutide, CagriSema, survodutide, tirzepatide, retatrutide, and orforglipron and situate them within obesity clinical practice ( We also propose practical strategies to mitigate gastrointestinal intolerance
Spencer Nadolsky (MD) is an obesity and lipid specialist physician with a passion for improving patient outcomes through innovative solutions
[1] [2] Ozempic is typically prescribed alongside lifestyle modifications, including diet and exercise, and may be used alone or in combination with other diabetes medications such as metformin
Instead, keep water nearby and take small sips throughout the day
However, the crossover, the year when it draws even and later ahead, could happen by 2030